{"id":14917,"date":"2024-11-25T20:55:06","date_gmt":"2024-11-25T12:55:06","guid":{"rendered":"https:\/\/flcube.com\/?p=14917"},"modified":"2024-11-25T20:55:14","modified_gmt":"2024-11-25T12:55:14","slug":"dizal-pharmaceutical-co-ltd-scales-back-private-placement-fundraising-to-usd-255-1-million","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14917","title":{"rendered":"Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million"},"content":{"rendered":"\n<p>China-based Dizal Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/688192:SHA\">SHA: 688192<\/a>) has announced revisions to its private placement plan, downsizing the initially disclosed proceeds from RMB 2.608 billion (USD 360 million) in April to RMB 1.848 billion (USD 255.1 million). The adjusted funds will be allocated towards new drug research and development, a global-aligned novel drug industrialization program, and supplementary working capital.<\/p>\n\n\n\n<p><strong>Allocation of Reduced Proceeds<\/strong><br>The company&#8217;s decision to reduce the private placement proceeds reflects a strategic reallocation of resources. The revised amount will now be directed towards:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>New drug research and development: This will include the advancement of innovative pharmaceutical products through various stages of research and development.<\/li>\n\n\n\n<li>Global-aligned novel drug industrialization program: This initiative aims to align with international standards and practices in the production and commercialization of novel drugs.<\/li>\n\n\n\n<li>Supplementary working capital: The funds will also be used to bolster the company&#8217;s operational liquidity and financial stability.<\/li>\n<\/ul>\n\n\n\n<p><strong>Implications for Dizal Pharmaceutical<\/strong><br>The revision of the private placement plan comes as Dizal Pharmaceutical continues to focus on expanding its pipeline and enhancing its capabilities in drug development and industrialization. The company remains committed to meeting the demands of the global pharmaceutical market while ensuring financial prudence in its capital raising efforts.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced revisions to its private placement plan,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":14918,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[191,20,981],"class_list":["post-14917","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-dizal-pharmaceutical","tag-finance","tag-sha-688192"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced revisions to its private placement plan, downsizing the initially disclosed proceeds from RMB 2.608 billion (USD 360 million) in April to RMB 1.848 billion (USD 255.1 million). The adjusted funds will be allocated towards new drug research and development, a global-aligned novel drug industrialization program, and supplementary working capital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14917\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14917\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-25T12:55:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-25T12:55:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/c5be7b6d85c691c4168557464a955d80.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14917#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14917\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million\",\"datePublished\":\"2024-11-25T12:55:06+00:00\",\"dateModified\":\"2024-11-25T12:55:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14917\"},\"wordCount\":213,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14917#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/c5be7b6d85c691c4168557464a955d80.png\",\"keywords\":[\"Dizal Pharmaceutical\",\"Finance\",\"SHA: 688192\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14917#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14917\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14917\",\"name\":\"Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14917#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14917#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/c5be7b6d85c691c4168557464a955d80.png\",\"datePublished\":\"2024-11-25T12:55:06+00:00\",\"dateModified\":\"2024-11-25T12:55:14+00:00\",\"description\":\"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced revisions to its private placement plan, downsizing the initially disclosed proceeds from RMB 2.608 billion (USD 360 million) in April to RMB 1.848 billion (USD 255.1 million). The adjusted funds will be allocated towards new drug research and development, a global-aligned novel drug industrialization program, and supplementary working capital.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14917#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14917\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14917#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/c5be7b6d85c691c4168557464a955d80.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/c5be7b6d85c691c4168557464a955d80.png\",\"width\":1080,\"height\":720,\"caption\":\"Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14917#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced revisions to its private placement plan, downsizing the initially disclosed proceeds from RMB 2.608 billion (USD 360 million) in April to RMB 1.848 billion (USD 255.1 million). The adjusted funds will be allocated towards new drug research and development, a global-aligned novel drug industrialization program, and supplementary working capital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14917","og_locale":"en_US","og_type":"article","og_title":"Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14917","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-25T12:55:06+00:00","article_modified_time":"2024-11-25T12:55:14+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/c5be7b6d85c691c4168557464a955d80.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14917#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14917"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million","datePublished":"2024-11-25T12:55:06+00:00","dateModified":"2024-11-25T12:55:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14917"},"wordCount":213,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=14917#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/c5be7b6d85c691c4168557464a955d80.png","keywords":["Dizal Pharmaceutical","Finance","SHA: 688192"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14917#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14917","url":"https:\/\/flcube.com\/?p=14917","name":"Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=14917#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=14917#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/c5be7b6d85c691c4168557464a955d80.png","datePublished":"2024-11-25T12:55:06+00:00","dateModified":"2024-11-25T12:55:14+00:00","description":"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced revisions to its private placement plan, downsizing the initially disclosed proceeds from RMB 2.608 billion (USD 360 million) in April to RMB 1.848 billion (USD 255.1 million). The adjusted funds will be allocated towards new drug research and development, a global-aligned novel drug industrialization program, and supplementary working capital.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14917#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14917"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=14917#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/c5be7b6d85c691c4168557464a955d80.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/c5be7b6d85c691c4168557464a955d80.png","width":1080,"height":720,"caption":"Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14917#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/c5be7b6d85c691c4168557464a955d80.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14917"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14917\/revisions"}],"predecessor-version":[{"id":14919,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14917\/revisions\/14919"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/14918"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14917"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14917"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}